| Autor: |
Diaz-Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL, Collaborative Famciclovir Genital Herpes Research Group, Diaz-Mitoma, F, Sibbald, R G, Shafran, S D, Boon, R, Saltzman, R L |
| Zdroj: |
JAMA: Journal of the American Medical Association; 9/9/98, Vol. 280 Issue 10, p887-892, 6p |
| Abstrakt: |
Context: Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences.Objective: To determine the efficacy and safety of famciclovir in the suppression of recurrent genital HSV infection.Design: A randomized, double-blind, placebo-controlled, parallel-group study.Setting: Thirty university, hospital, or private outpatient referral centers in Canada and Europe.Patients: A total of 455 patients (223 men, 232 women) aged 18 years or older with a history of 6 or more episodes of genital herpes during 12 of the most recent 24 months, in the absence of suppressive therapy, received study medication.Intervention: Oral famciclovir, 125 mg or 250 mg 3 times daily or 250 mg twice daily, or placebo for 52 weeks.Main Outcome Measures: Time to the first recurrence of genital HSV infection; the proportion of patients remaining free of HSV recurrence at 6 months; frequency of adverse events.Results: In an intent-to-treat analysis, famciclovir significantly delayed the time to the first recurrence of genital herpes at all dose regimens (hazard ratios, 2.9-3.3; P<.001); median time to recurrence for famciclovir recipients was 222 to 336 days compared with 47 days for placebo recipients. The proportion of patients remaining free of HSV recurrence was approximately 3 times higher in famciclovir recipients (79%-86%) than in placebo recipients (27%) at 6 months (relative risks, 2.9-3.1; P<.001); efficacy was maintained at 12 months. Famciclovir was well tolerated with an adverse experience profile comparable to placebo.Conclusions: Oral famciclovir (125 mg or 250 mg 3 times daily or 250 mg twice daily) is an effective, well-tolerated treatment for the suppression of genital HSV infection in patients with frequent recurrences. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
